Company intelligence / Profile preview

3H Pharmaceuticals

Shanghai, Shanghai Shi, Chinacn.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

3H Pharmaceuticals, founded in Shanghai's Zhangjiang High-tech Zone in March 2021, focuses on the development of innovative therapies for cancer and immune-related diseases. The company has a diverse pipeline including small molecules and antibodies targeting neoplasms—especially solid tumors with FGFR2 mutations—and immune system disorders. Its lead asset, "3HP-2827," targets FGFR2-mutant solid tumors and has reached the IND approval stage as of June 2025. Several other programs are in preclinical or discovery phases. No clinical results have been published yet.

Therapeutic areas: ImmunologyOncology
Modalities: Small moleculeAntibodyBiological products
Industry: Biotech

Drug pipeline

4 assets

3HP-2827

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on 3H Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3H Pharmaceuticals.

Explore the full profile